Table 3.

Efficacy and safety outcomes for DOAC and warfarin use, stratified by polypharmacy status

	Polypharmacy	DOAC	Warfarin	RR	I2	P value
Stroke	Yes	339 (2.9%)	410 (3.6%)	0.90 [0.70–1.10]	0%	0.31
	No	142 (3.1%)	161 (3.4%)	0.82 [0.70–0.94]
Death from any cause	Yes	931 (8.0%)	1012 (8.8%)	0.92 [0.84–0.99]	0%	0.82
	No	254 (5.5%)	289 (6.1%)	0.90 [0.75–1.04]
Major bleeding	Yes	603 (5.2%)	652 (5.7%)	0.94 [0.64–1.24]	85%	0.15
	No	119 (2.6%)	196 (4.1%)	0.61 [0.29–0.93]
Intracranial hemorrhage	Yes	80 (0.7%)	156 (1.4%)	0.53 [0.18–0.87]	69%	0.99
	No	27 (0.6%)	50 (1.1%)	0.53 [0.11–0.94]
CRNM bleed	Yes	1081 (9.3%)	1179 (10.3%)	0.85 [0.56–1.14]	90%	0.62
	No	422 (9.1%)	416 (8.8%)	0.96 [0.64–1.27]
Net clinical benefit *	Yes	1265 (10.9%)	1415 (12.3%)	0.88 [0.82–0.95]	4%	0.43
	No	343 (7.4%)	417 (8.9%)	0.83 [0.71–0.95]

*ARISTOTLE, stroke/SE/major bleed/death; ROCKET, stroke/SE/fatal bleed/vascular death